Stable angina pectoris of coronary heart disease
Conditions
Interventions
Qishen Yiqi dropping pills group :Qishen Yiqi drop pills, orally, 1 bag eath time, three times a day
Shexiang Baoxin pill group :Shexiang Baoxin pills, orally, 2 pills each time, three times a day
Danlou tablet group :Danlou tablets, orally, 5 tablets each time, three times a day
Control group:Taking aspirin enteric-coated tablets orally half an hour after meals, 100mg each time, once a day
Sponsors
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Consistent with the diagnosis of stable angina pectoris of coronary heart disease; 2. Canadian Society of Cardiovascular Disease (CCS) angina grading ? ~ ?; 3. Aged range from 18 to 65 years (including 18 and 65 years old) at the time of informed consent, no gender limit; 4. Voluntarily participate in this clinical trial, give informed consent and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. The following criteria must not be met in the screening to be included in the test: other diseases complicated with chest pain manifestations: fresh rib fracture, costochondritis, chest myofascitis, radiculopathy, etc.; 2. Combined with other causes affecting ECG ST-T changes: myocardial hypertrophy, left bundle branch block, right bundle branch block, preexcitation syndrome, electrolyte disturbance, application of cardiac pacemaker, etc.; 3. Malignant hypertension, severe heart failure, severe arrhythmia, acute cerebrovascular disease, etc.; 4. Myocardial infarction or infarction symptoms occurred within 3 months before screening; 5. Received surgical treatment within 3 months prior to screening or required elective surgery during the trial; 6. Severe diseases of digestive system, hematopoietic system and other systems, such as active digestive ulcer and coagulation dysfunction; 7. Combined with other conditions that absolute or relative prohibition of 6-minute walking test: resting heart rate > 120 beats/min, systolic blood pressure > 180mmHg and diastolic blood pressure > 100mmHg; 8. Patients with severe anemia, glaucoma or increased intracranial pressure; 9. Allergic constitution and allergy to known ingredients used in the test; 10. Liver function index (ALT, AST) > 1.5 times the upper limit of normal reference value, or renal function index (Scr) > upper limit of normal reference value; 11. Combination of mental illness or mental retardation; 12. History of alcohol dependence, drug abuse or addiction; 13. Pregnant or lactating patients or patients who have a birth plan during the experiment and cannot take effective contraceptive measures; 14. Participated in other clinical trials within the last 3 months; 15. According to the judgment of the researcher, it is not appropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seattle angina scale score, SAQ; | — |
Secondary
| Measure | Time frame |
|---|---|
| 6-minute walk distance;Angina symptom score;Nitroglycerin stop rate;TCM syndrome score; | — |
Countries
China
Contacts
Public ContactZhang Li
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine
Outcome results
None listed